Eximore

Eximore
Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.
About
What does Eximore do?
Eximore Ltd is a biopharmaceutical company focused on the development, and commercialization of our innovative proprietary "pack and release" punctal plug technology therapy for diseases of the eye. Eximore is positioned to become a central player in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current eye drops standard of care by developing a non-invasive, sustained-release alternative. With a focus on advancing our Glau…
What is Eximore's revenue?
StartupHub estimates Eximore's annual revenue at $1.2M (range $667K to $1.9M, 64% confidence), based on comparable companies in the sector.
What is Eximore's valuation?
StartupHub estimates Eximore's effective valuation at $38.8M (range $25.0M to $60.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Eximore raised?
Eximore has raised a total of $10M in funding. The most recent round on record is Series A.
Where is Eximore headquartered?
Eximore is headquartered in Tel Aviv, Israel.
When was Eximore founded?
Eximore was founded in 2014.
What industry does Eximore operate in?
Eximore operates in Life Sciences, Biopharmaceutical, Biotech, MedTech, Drug Discovery, Clinical Trials.
How many employees does Eximore have?
Eximore has approximately 7 people on record.
No comments yet. Be the first to share your take.
